One promising attribute of PD-1 in cancer immunotherapy is that the expression of PD-1 ligands, especially PD-L1, has been shown to be upregulated in a variety of tumors, and blockade of PD-L1 signal can sensitize tumors to cytotoxic T lymphocyte (CTL) killing [25]. This evidence concerns the gene CD274 and cancer.